The FDA has authorized Mayo Clinic to offer mesenchymal stem cells as part of the Regenerative Nephrology Compassionate Use Program. This is an expanded access program.
Diabetic kidney disease affects a growing proportion of people with diabetes and remains the leading cause of end-stage renal ...
Dr Mark Kris breaks down the lazertinib-amivantamab data, noting that the combo shows benefit but fails to address key ...
An American Heart Association presidential advisory in 2023 introduced a new term: cardiovascular-kidney-metabolic syndrome.
Neighborhood-level social determinants of health were associated with varying cancer risks and greater mortality among kidney ...
Beyond hazard ratios, investigators used restricted mean survival time (RMST) analysis to compare survival gains across trialed ICI combinations for mRCC.
In 2026, Robert F. Kennedy Jr.'s health policy changes will start playing out on GLP-1s, dietary guidelines, and rural health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback